Drug intelligence / Profile preview

CV Defense

Development stage: Unknown
Lead developer: CV Sciences
Modality: Small Molecules
Administration: Oral

Overview

CV Defense is an oral multi-ingredient dietary supplement developed by CV Sciences and marketed as a daily immune support product rather than a pharmaceutical therapy. The formulation centers on palmitoylethanolamide, a naturally occurring fatty acid amide that is described as interacting with the endocannabinoid system, and also contains vitamins A and D3, zinc, selenium, and organic Reishi mushroom extract with beta-glucans. It is intended to support barrier, innate, and adaptive immune function for general wellness use, not to treat a specific disease, and was launched in 2020 as part of the company's immunity-focused consumer product line.

Brand names: CV Defense

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on CV Defense.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CV Defense.

Explore the full profile